Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients

References

• HaoJZhaoPChenWChinese Cancer Registry Annual Report 2012BeijingMilitary Medical Science Press2013 Chinese
   Google Scholar
• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• SheJYangPHongQBaiCLung cancer in China: challenges and interventionsChest201314341117112623546484
   PubMed Web of Science ®Google Scholar
• YangPAllenMSAubryMCClinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003Chest2005128145246216002972
   PubMed Web of Science ®Google Scholar
• RinaldiMCauchiCGridelliCFirst line chemotherapy in advanced or metastatic NSCLCAnn Oncol200617Suppl 5v64v6716807466
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• NormannoNBiancoCDe LucaAMaielloMRSalomonDSTarget-based agents against ErbB receptors and their ligands: a novel approach to cancer treatmentEndocr Relat Cancer200310112112653668
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• ReckMvan ZandwijkNGridelliCErlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment studyJ Thorac Oncol20105101616162220736854
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• WuYLLeeJSThongprasertSIntercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trialLancet Oncol201314877778623782814
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• WuYLLiaoMLQinSKSunYZhouCCEfficacy and safety of erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patientsZhonghua Zhong Liu Za Zhi2010322148151 Chinese20403248
   PubMedGoogle Scholar
• WuYLKimJHParkKZaatarAKlingelschmittGNgCEfficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN studyLung Cancer201277233934522494567
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• MokTLuiPLamKNovel mutations and mutation pattern of epidermal growth factor receptor (EGFR) gene in Chinese patients with primary lung adenocarcinomaJ Clin Oncol20072518 Suppl 7667426s
   Web of Science ®Google Scholar
• KosakaTYatabeYOnozatoRPrognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early prognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early stage lung adenocarcinomaJ Clin Oncol20072518 Suppl7574
   Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• AnSJChenZHSuJIdentification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking statusPLoS One201276e4010922768234
   PubMed Web of Science ®Google Scholar
• HeigenerDFWuYLvan ZandwijkNMaliPHorwoodKReckMSecond-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST studyLung Cancer201174227427921439671
   PubMed Web of Science ®Google Scholar
• MokTWuYLAuJSEfficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancerJ Thorac Oncol20105101609161520808255
   PubMed Web of Science ®Google Scholar
• YoshioOMasahikoAKazuhiroARandomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA)J Clin Oncol2013Suppl 318006
   Google Scholar
• YangJJChengYZhaoMFA phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806)J Clin Oncol2013Suppl 318042
   Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol200725121545155217442998
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• Hoffmann-La RocheA Study of Tarceva (Erlotinib) Versus Gemcitabine/Cisplatin as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With EGFR MutationsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated January 20, 2014]. Available from: http://clinicaltrials.gov/show/NCT01342965 NLM identifier: NCT01342965Accessed January 24, 2014
   Google Scholar
• XueCHuZJiangWNational survey of the medical treatment status for non-small cell lung cancer (NSCLC) in ChinaLung Cancer201277237137522579298
   PubMed Web of Science ®Google Scholar
• MokTSWuYLYuCJRandomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancerJ Clin Oncol200927305080508719738125
   PubMed Web of Science ®Google Scholar
• WuYLLeeJSThongprasertSIntercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trialLancet Oncol201314877778623782814
   PubMed Web of Science ®Google Scholar
• GridelliCMaionePRossiAPotential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?Oncologist200914213714719190239
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• BelaniCPSchreederMTSteisRGCetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 studyCancer200811392512251718816622
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• FidiasPMDakhilSRLyssAPPhase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerJ Clin Oncol200927459159819075278
   PubMed Web of Science ®Google Scholar
• BrodowiczTKrzakowskiMZwitterMCisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialLung Cancer200652215516316569462
   PubMed Web of Science ®Google Scholar
• CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet200937496991432144019767093
   PubMed Web of Science ®Google Scholar
• Paz-AresLde MarinisFDediuMMaintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trialLancet Oncol201213324725522341744
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• ZhangLMaSSongXGefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trialLancet Oncol201213546647522512843
   PubMed Web of Science ®Google Scholar
• GossGDO’CallaghanCLorimerIGefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 studyJ Clin Oncol201331273320332623980091
   PubMed Web of Science ®Google Scholar
• RichardsonFRichardsonKSennelloGBiomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT)J Clin Oncol200927Suppl7520
   Google Scholar
• Guangdong Association of Clinical TrialsGefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation (ADJUVANT)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated September 5, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01405079?term=NCT01405079&rank=1 NLM identifier: NCT01405079Accessed January 24, 2014
   Google Scholar
• Chinese Lung Cancer Surgical GroupErlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR MutationsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated December 21, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01410214?term=NCT01410214&rank=1 NLM identifier: NCT01410214Accessed January 24, 2014
   Google Scholar
• Guangdong Provincial People’s HospitalInduction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated June 23, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT00600587?term=NCT00600587&rank=1 NLM identifier: NCT00600587Accessed January 24, 2014
   Google Scholar
• Guangdong Association of Clinical TrialsErlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer (EMERGING)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated September 5, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01407822?term=NCT01407822&rank=1 NLM identifier: NCT01407822Accessed January 24, 2014
   Google Scholar
• HanBaohuiErlotinib as Neoadjuvant Treatment in Patients With Stage III A N2 NSCLC With Activating EGFR Mutation (ML25444)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated March 6, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01217619?term=NCT01217619&rank=1 NLM identifier: NCT01217619Accessed January 24, 2014
   Google Scholar
• KuoCHLinSMLeeKYSubsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistanceClin Lung Cancer2010111515620085868
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKGaleCMPF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibCancer Res20076724119241193218089823
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• SchillerJHAkerleyWLBruggerWResults from ARQ 197–209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)J Clin Oncol201028Suppl 18LBA7502
   Web of Science ®Google Scholar
• SpigelDRErvinTJRamlauRFinal efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLCJ Clin Oncol201129Suppl7505
   Web of Science ®Google Scholar
• JannePAWangXSocinskiMARandomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trialJ Clin Oncol201230172063206922547605
   PubMed Web of Science ®Google Scholar
• YangJJChenHJYanHHClinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancerLung Cancer2013791333923079155
   PubMed Web of Science ®Google Scholar
• ParkKTsaiCAhnMASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)J Clin Oncol201230SupplTPS7614
   Google Scholar
• AstraZenecaA Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated November 7, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01544179?term=NCT01544179&rank=1 NLM identifier: NCT01544179Accessed January 24, 2014
   Google Scholar
• ZhuangHQYuanZYWangJWangPZhaoLJZhangBLResearch progress on criteria for discontinuation of EGFR inhibitor therapyOnco Targets Ther2012526327023082072
   PubMed Web of Science ®Google Scholar